Problems in the treatment of hypertension.
D018663:Adrenergic Agents / Q000009:adverse effects; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001581:Benzothiadiazines; D003000:Clonidine / Q000009:adverse effects; D004232:Diuretics; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000009:adverse effects; D010349:Patient Compliance; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects; D013997:Time Factors; D014665:Vasodilator Agents / Q000009:adverse effects
D018663:Adrenergic Agents; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D014665:Vasodilator Agents; D008750:Methyldopa; D003000:Clonidine